Drugs / AZD7762
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00937664 | Jul 2009 → Feb 2011 | cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00473616 | May 2007 → Jan 2011 | high grade malignant neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00413686 | Dec 2006 → May 2010 | cancer | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7762 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473616 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL2041933 ↗ |
| Modality | Small molecule | — CHEMBL2041933 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00413686 ↗ |
| Target | CHEK1 | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL2041933 ↗ |